Compare Icl Group Ltd (ICL) vs Royalty Pharma plc Class A Ordinary Shares (RPRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Icl Group Ltd vs Royalty Pharma plc Class A Ordinary Shares — how do they compare? Icl Group Ltd trades at $5.03 (market cap $6.47B), while Royalty Pharma plc Class A Ordinary Shares trades at $56.88 (market cap $25.27B). The key difference: Royalty Pharma plc Class A Ordinary Shares is far larger — about 3.9× Icl Group Ltd's market cap, and Icl Group Ltd pays the higher dividend (4.11%). Which is the better fit depends on your goals — on Pluang, investors hold Icl Group Ltd for 56 Days and Royalty Pharma plc Class A Ordinary Shares for 1 Days on average.
| ICL | RPRX | |
|---|---|---|
Market Cap | $6.47B | $25.27B |
Volume | 1,387,140 | 3,671,183 |
Sector | Basic Materials | Health |
52-Week High | $6.84 | $63.96 |
52-Week Low | $4.80 | $35.44 |
Typical Hold Time | 56 Days | 1 Days |
Enterprise Value | $9.11B | $32.50B |
Dividend Yield | 4.11% | 1.66% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ICL trades at $5.02, down 1.18% today, with a bearish technical signal from moving averages. The company reported Q2 2026 EPS of $0.12, beating estimates, but revenue and net income have declined from 2022 peaks. Valuation appears reasonable with P/E of 20.83 and P/S of 0.84, while analyst consensus is entirely Hold with a $6.08 price target. Recent news highlights dividend strength and cost-transformation initiatives.
The outlook is mixed: earnings beats and dividend yield offer support, but declining profitability and industry headwinds pose challenges. Upside exists if cost cuts and price stabilization materialize, though margin pressure and competitive threats remain key risks for investors.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Icl Group Ltd
ICL Group Ltd is a manufacturer of products based on minerals. The firm is comprised of four segments: phosphate solutions, potash, industrial products, and innovative agriculture solutions (IAS). These segments all contribute to the company's development of agriculture, food, and engineered material products and services. The company mines and manufactures potash and phosphates to be used as ingredients in fertilizers and serve as a component in the pharmaceutical and food additives industries. It is also engaged in industrial additives and materials, including flame retardants, phosphate salts, specialty phosphate blends, purified phosphoric acid, electronic-grade specialty phosphoric acids. Its geographical segments are Europe, Asia, North & South America, and the Rest of the world.
Read more on ICL →About Royalty Pharma plc Class A Ordinary Shares
Royalty Pharma acquires interests in royalties from biopharmaceutical products. Its model gives it exposure to medicines developed and sold by other life sciences companies.
Read more on RPRX →
